

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number  
**WO 03/105837 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/405,**  
C07D 209/24

**KAPA, Prasad, Koteswara** [US/US]; 4 Faber Road, Parsippany, NJ 07054 (US). **SUTTON, Paul, Allen** [US/US]; 34 Irvington Road, Parsippany, NJ 07054 (US).

(21) International Application Number: PCT/EP03/06195

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date: 12 June 2003 (12.06.2003)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Data:  
60/388,318 13 June 2002 (13.06.2002) US

(71) Applicant (*for all designated States except AT, US*): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Stasse 59, A-1230 Vienna (AT).

Published:


— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CHEN, Guang-Pei** [US/US]; 33 Preston Drive, Livingston, NJ 07039 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CALCIUM SALTS OF INDOLE DERIVED STATINS



(IA)

(57) Abstract: The present invention provides calcium salts of indole derived statins of the formula (IA) wherein R<sub>1</sub> is alkyl, cycloalkyl or aralkyl; R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are independently hydrogen, halogen or alkyl; R<sub>5</sub> and R<sub>6</sub> are independently hydrogen, halogen, alkyl, cycloalkyl, aralkyl, alkoxy or aralkoxy; and the hydroxyl group at the 3 position is in the R-configuration and at the 5 position in the S-configuration; or an enantiomer thereof; or a hydrate thereof; as obtainable by the methods of the present invention. More specifically, the invention provides a calcium salt of

formula (IA) wherein R<sub>1</sub> is isopropyl, R<sub>2</sub> is fluorine and R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are hydrogen, designated herein as Fluvastatin calcium, in a highly crystalline form. Furthermore, the present invention is directed to methods for the preparation of the crystalline Fluvastatin calcium, and to pharmaceutical compositions comprising the crystalline form.